semaglutide injections denver Semaglutide Medical Weight Loss Colorado

Long-term studies of patients on continuous GLP-1 therapy show sustained weight loss maintenance, improved cardiovascular outcomes, and normalized appetite signaling over years of treatment

A 57-year-old woman with a BMI of 45.5 and prior breast cancer developed an occlusive DVT of her left subclavian vein after eight months on tirzepatide 10 mg weekly (tirzepatide is a dual GLP-1/GIP agonist)

doi: 10.1161/ATVBAHA.107.159327 39 MenghiniRCasagrandeVRizzaSFedericiM

Tirzepatide affects both glucose and appetite regulation, so plasma donation may cause more fatigue in some users due to fluid and protein loss combined with reduced hunger sensation

Ask your doctor about medications or supplements targeting weight loss with fewer hormonal impacts